Moderna : MRNA

All Moderna Articles

127 Articles

Chris Lange | Mar 11, 2020 at 11:06 AM EDT

Coronavirus Stocks See Rising Tide in Short Interest

The February 28 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Mar 5, 2020 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Abbott Labs, Alexion, Avis Budget, DexCom, J&J, Marvell, Moderna, Snap, Splunk, Zoom Video and More

Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, Alexion Pharmaceuticals, Avis Budget, DexCom, Johnson & Johnson, Marvell Technology,…

Jon C. Ogg | Feb 13, 2020 at 3:38 PM EST

How the Coronavirus Will Harm GDP and Businesses in 2020

With more than 60,000 reported cases of the coronavirus and nearly 1,400 deaths worldwide along with quarantines and travel restrictions,…

Jon C. Ogg | Feb 10, 2020 at 4:35 PM EST

Moderna Commits to $500 Million Capital Raise, With More Possible

Moderna Inc. (NASDAQ: MRNA) had been the biggest biotech initial public offering ever. The company was quite unlucky in the…

Chris Lange | Jan 27, 2020 at 10:05 AM EST

12 Stocks Surging That Could Help Treat or Fight Coronavirus

As with almost all pandemic scares and other national and global issues, some speculative stocks manage to see their shares…

Jon C. Ogg | Jan 26, 2020 at 11:25 AM EST

As Coronavirus Spreads, Sensitive China, US, Global Economies Face Great Risks

The Wuhan Coronavirus has escaped China, with the number of cases and the death toll rising. The economic impact beyond…

Jon C. Ogg | Jan 25, 2020 at 2:35 PM EST

Beyond Rising Deaths, Wuhan Coronavirus Already Hits China, US, Global Economies

The Wuhan Coronavirus has already left China and hit neighboring countries, the U.S. and even in Europe in Australia. As…

1 … 7 8 9

Moderna : MRNA

All Moderna Articles

Coronavirus Stocks See Rising Tide in Short Interest

Top Analyst Upgrades and Downgrades: Abbott Labs, Alexion, Avis Budget, DexCom, J&J, Marvell, Moderna, Snap, Splunk, Zoom Video and More

How the Coronavirus Will Harm GDP and Businesses in 2020

Moderna Commits to $500 Million Capital Raise, With More Possible

12 Stocks Surging That Could Help Treat or Fight Coronavirus

As Coronavirus Spreads, Sensitive China, US, Global Economies Face Great Risks

Beyond Rising Deaths, Wuhan Coronavirus Already Hits China, US, Global Economies

Why Is Institutional Money Pouring Into XRP ETFs While Fleeing Bitcoin and Ethereum?

U.S. Interest Expense Just Hit $1.6 Trillion Annually. Peter Schiff Warns a Dollar Crisis Arrives When It Hits $2 Trillion.

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

64-Year-Old Tech Exec Holds $1.6 Million in One Stock. The Wrong Move Could Cost $400,000.

Why Is Institutional Money Pouring Into XRP ETFs While Fleeing Bitcoin and Ethereum?

U.S. Interest Expense Just Hit $1.6 Trillion Annually. Peter Schiff Warns a Dollar Crisis Arrives When It Hits $2 Trillion.

Moderna : MRNA

All Moderna Articles

Coronavirus Stocks See Rising Tide in Short Interest

Top Analyst Upgrades and Downgrades: Abbott Labs, Alexion, Avis Budget, DexCom, J&J, Marvell, Moderna, Snap, Splunk, Zoom Video and More

How the Coronavirus Will Harm GDP and Businesses in 2020

Moderna Commits to $500 Million Capital Raise, With More Possible

12 Stocks Surging That Could Help Treat or Fight Coronavirus

As Coronavirus Spreads, Sensitive China, US, Global Economies Face Great Risks

Beyond Rising Deaths, Wuhan Coronavirus Already Hits China, US, Global Economies

Why Is Institutional Money Pouring Into XRP ETFs While Fleeing Bitcoin and Ethereum?

U.S. Interest Expense Just Hit $1.6 Trillion Annually. Peter Schiff Warns a Dollar Crisis Arrives When It Hits $2 Trillion.

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

Featured Reads

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

64-Year-Old Tech Exec Holds $1.6 Million in One Stock. The Wrong Move Could Cost $400,000.